Adma Biologics (ADMA) Non-Current Assets (2011 - 2025)

Adma Biologics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $157.7 million for Q4 2025.

• Quarterly Non-Current Assets changed 0.29% year-over-year to $157.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $641.3 million (up 70.18% YoY) and the FY2025 annual result came in at $157.7 million, changed 0.29% from the prior year.
• Non-Current Assets was $157.7 million for Q4 2025 at Adma Biologics, down from $166.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $166.0 million in Q3 2025 and bottomed at $58.4 million in Q1 2021.
• A 5-year average of $93.4 million and a median of $74.9 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2021 — Non-Current Assets soared 189.85% — and 2023, when it fell 7.55%.
• Adma Biologics' Non-Current Assets stood at $67.5 million in 2021, then advanced by 15.6% to $78.1 million in 2022, then dropped by 7.55% to $72.2 million in 2023, then soared by 117.92% to $157.3 million in 2024, then climbed by 0.29% to $157.7 million in 2025.
• Business Quant data shows ADMA's Non-Current Assets at $157.7 million in Q4 2025, $166.0 million in Q3 2025, and $158.8 million in Q2 2025.